Takhzyro use in teenagers and adults with hereditary angioedema in South Korea

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the safety and effectiveness of Takhzyro in routine clinical practice for patients aged 12 and older with hereditary angioedema in South Korea. No new treatment is given by researchers; data are collected from standard medical care as prescribed by treating physicians. Participants may have multiple visits to the study sites to capture real-world outcomes and adverse events. The study relies on existing medical records and physician judgment to monitor safety and perceived efficacy in everyday use.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Participants aged 12 years or older at time of initiation of Takhzyro.
2. Participants who are treated or will be treated with Takhzyro according to the approved label of South Korea.
3. The participant or legally authorized representative agrees to participate.

Exclusion criteria:

1. Any of the contraindications included in the Prescribing Information (PI) for TAKHZYRO apply.
2. Participant is currently enrolled in an interventional trial.

Where it's running

• Ajou University Hospital
  Suwon, Gyeonggi-do, South Korea Recruiting
• Seoul National University Hospital
  Seoul, South Korea Recruiting
• Ewha Womans University Hospital
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Takeda Contact
• Email: medinfoUS@takeda.com
• Phone: +1-877-825-3327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term treatment with ADX-324 for people with hereditary angioedema

  This extension will try additional doses of ADX-324 (onvuzosiran) to see if continuing the drug is safe and helps people with Type I or II hereditary angioedema who finished the earlier Phase 3 trial.

  Recruiting at 3 sites Phase 3 ADARx Pharmaceuticals, Inc. · Litchfield Park, Arizona and 47 other locations · NCT07428499

• Donidalorsen for children with hereditary angioedema

  This trial tests if donidalorsen is safe and how it is processed in the body for children aged 2 to under 12 with hereditary angioedema types I or II.

  Recruiting at 18 sites Phase 3 Ionis Pharmaceuticals, Inc. · Santa Monica, California and 17 other locations · NCT07298447

• C1-Inhibitor Function Test to Diagnose HAE in Algeria

  A test that measures C1-inhibitor function is being tried to see if it can accurately diagnose hereditary angioedema in patients in Algeria.

  Recruiting Takeda · Algiers · NCT07293364

• Oral deucrictibant to prevent and treat hereditary angioedema attacks

  This trial tests whether daily oral deucrictibant XR can prevent angioedema attacks and whether deucrictibant capsules can quickly relieve acute attacks in adults with bradykinin-mediated hereditary angioedema.

  Recruiting Phase 1/2 Institute for Asthma and Allergy · Wheaton, Maryland · NCT07046806

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.